GLP-1 cost pressures lead Cigna to cut employee obesity drug coverage
Cigna's decision to end employee coverage for obesity-related GLP-1 drugs has renewed attention on one of healthcare's fastest-growing spending categories. The move affects Wegovy and Zepbound but not diabetes treatments, and comes as employers, insurers and health systems continue reviewing the long-term cost of weight-loss medicines.
Cigna will stop covering obesity-related GLP-1 drugs for employees, a decision that reflects wider debates over healthcare costs as demand for weight-loss medicines continues growing.
Key Highlights
- Cigna will end employee coverage for obesity-related GLP-1 drugs on July 1.
- Wegovy and Zepbound remain affected, while diabetes-related GLP-1 coverage continues.
- Rising obesity-drug spending is prompting employers to review healthcare benefits.
- Demand for GLP-1 medicines continues to grow across several major healthcare markets.
- Cigna reported $68.5 billion in first-quarter 2026 revenue.
The Cigna Group will resume non-covered claims for GLP-1 obesity medications for its company-sponsored health plan on July 1, bringing one of the healthcare industry's fastest-growing costs back to the forefront.
The ruling applies to weight-loss drugs such as Wegovy and Zepbound, but not to GLP-1 drugs prescribed for Type 2 diabetes. The change applies only to Cigna's employee health plan and may not be automatically applied to other employers' health plans it administers.
The Cost Debate Moves Centre Stage
Cigna's move follows insurers and employers as they deliberate on the long-term expense of obesity treatments.
Consumption of GLP-1 drugs has surged in the last two years, with drugs like Wegovy and Zepbound gaining popularity. In the U.S., monthly costs of treatment can be more than $1,000, before rebates and discounts, and obesity coverage is among the healthcare spending issues most closely watched.
Business Group on Health's 2025 Large Employer Health Care Strategy Survey located that a lot of large employers were reevaluating obesity-drug benefits due to cost increases and increased need.
Beyond One Company's Health Plan
The development comes as health authorities in a number of countries grapple over whether to fund the treatment of obesity more widely.
Wegovy has been available for private prescription in Australia in recent years, and access and cost discussions continue to be hot topics for broader reimbursement. Some obesity treatments are available on the National Health Service (NHS) in the United Kingdom, but with certain criteria.
Obesity drugs have become a clear target for the future expenditure buckets of payors such as insurance companies, governments and employers.
Employees Keep Some Treatment Options
Employers also can continue to provide obesity medication to workers through manufacturer programs or other means of acquisition, but it won't be included in the health-plan deductible.
Other weight-management programs and some older weight-loss drugs will continue to be covered, the company added.
Cigna has a world-wide workforce of about 68,000. The company's Q1 2026 earnings include earnings of $68.5 billion, up 5% from a year ago and net income of approximately $1.7 billion.
The new policy reflects the influence of the swift evolution of GLP-1 medications in the context of employer-sponsored health plans.
FAQ
Q1. Why is Cigna ending coverage for Wegovy and Zepbound for employees?
Cigna is removing obesity-related GLP-1 drug coverage from its employee health plan while continuing coverage for diabetes treatments.
Q2. Does the Cigna policy change affect all health insurance customers?
No. The change applies only to employees enrolled in Cigna's internal health plan and does not automatically affect client-sponsored plans.
Q3. Why are GLP-1 weight-loss drugs becoming a challenge for employers?
High treatment costs and growing demand have made GLP-1 medications one of the fastest-rising healthcare expenses for many employers.
Follow Inspirepreneur Magazine for daily global business news.